Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 90, No. 1-2, 2012
Issue release date: August 2012
Section title: Review
Free Access
Pharmacology 2012;90:102–109

Darunavir: A Critical Review of Its Properties, Use and Drug Interactions

Ruela Corrêa J.C.a · D’Arcy D.M.c · dos Reis Serra C.H.b · Nunes Salgado H.R.a
aDrugs and Medicines Quality Control Laboratory, School of Pharmaceutical Sciences University Estadual Paulista, Araraquara, and bSchool of Pharmaceutical Sciences University of São Paulo, São Paulo, Brazil; cSchool of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland
email Corresponding Author

Josilene Chaves Ruela Corrêa

Drugs and Medicines Quality Control Laboratory

School of Pharmaceutical Sciences University Estadual Paulista

Rod. Araraquara-Jaú, km 1, 14801–902, Araraquara (Brazil)

Tel. +55 1633 014 681, E-Mail josilenechavescorrea@gmail.com

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Darunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wild-type HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadminister other medications for reasons including the prevention or treatment of opportunistic infections, treatment of concomitant illnesses and management of antiretroviral side effects. Drug interactions have been observed between darunavir and other drugs. New and more comprehensive drug interaction studies will be required since the increase in life expectancy of patients often brings new comorbidities and the concomitant use of different drugs. This paper discusses the impact of the use of darunavir in the treatment of HIV-infected patients, its pharmacological and physical-chemical properties, its drug interactions, and challenges that remain in order to ensure safety and compliance of treatment.

© 2012 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Review

Received: May 25, 2012
Accepted: June 04, 2012
Published online: July 12, 2012
Issue release date: August 2012

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 1

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: http://www.karger.com/PHA

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.